Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12462583 | 0.87 | ALDH1A1 (0.43) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL2612028 | 0.83 | — | — | |
| SCHEMBL320036 | 0.80 | MEN1 (0.34) | ALDH1A1TSHRLMNACYP2C19KMT2A | |
| SCHEMBL14104292 | 0.80 | CYP1A2 (0.62) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL2920990 | 0.79 | CYP1A2 (0.59) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL16877114 | 0.79 | CYP1A2 (0.54) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL9458907 | 0.78 | ALDH1A1 (0.42) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL15181954 | 0.77 | SIRT2 (0.31) | KMT2AMEN1CYP2C9 | |
| SCHEMBL3195737 | 0.77 | ALDH1A1 (0.63) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL4075330 | 0.74 | SIRT2 (0.35) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441761-B2 | Conjugation reagents and methods using 1,2-cyclohexanediones | Encodia, Inc. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20230295222-A1 | Conjugation Reagents and Methods Using 1,2-Cyclohexanediones | Encodia, Inc. (US) | 2023-09-21 | — | — | US | disclosed |
| US-11639366-B2 | Conjugation reagents and methods using 1,2-cyclohexanediones | Encodia, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| CN-111406050-B | Indoleamine 2, 3-dioxygenase inhibitors and uses thereof | 厦门宝太生物科技股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20220144885-A1 | CONJUGATION REAGENTS AND METHODS USING 1,2-CYCLOHEXANEDIONES | Encodia, Inc. (US) | 2022-05-12 | — | — | US | disclosed |
| WO-2022094148-A1 | CONJUGATION REAGENTS AND METHODS USING 1,2-CYCLOHEXANEDIONES | Encodia, Inc. (US) | 2022-05-05 | — | — | WO | disclosed |
| CN-111518076-B | Preparation method of indoleamine-2, 3-dioxygenase (IDO) inhibitor | 杭州阿诺生物医药科技有限公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-111518077-B | Preparation method of novel anti-tumor IDO inhibitor | 杭州阿诺生物医药科技有限公司 | 2021-02-26 | — | — | CN | disclosed |
| CN-111518077-A | Preparation method of novel anti-tumor IDO inhibitor | 杭州阿诺生物医药科技有限公司 | 2020-08-11 | — | — | CN | disclosed |
| CN-111518076-A | Preparation method of indoleamine-2, 3-dioxygenase (IDO) inhibitor | 杭州阿诺生物医药科技有限公司 | 2020-08-11 | — | — | CN | disclosed |
| CN-111406050-A | Indoleamine 2, 3-dioxygenase inhibitors and uses thereof | 杭州阿诺生物医药科技有限公司 | 2020-07-10 | — | — | CN | disclosed |
| WO-2019141153-A1 | INDOLAMINE 2,3-DIOXYGENASE INHIBITOR AND USE THEREOF | 杭州阿诺生物医药科技有限公司 | 2019-07-25 | — | — | WO | disclosed |
| US-4988699-A | Treatment of psychological disorders such as schizophrenia, as antipsychotic agents and hypotensive agents | WARNER-LAMBERT COMPANY (US) | 1991-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144885-A1 | CONJUGATION REAGENTS AND METHODS USING 1,2-CYCLOHEXANEDIONES | TNNI3, CHD1, TNNT2 | ALDH1A1 1150/4885CYP1A2 3064/4885TSHR 786/4885 |
| US-12441761-B2 | Conjugation reagents and methods using 1,2-cyclohexanediones | TNNI3, CHD1, TNNT2 | ALDH1A1 1179/4885CYP1A2 2803/4885TSHR 827/4885 |
| US-20230295222-A1 | Conjugation Reagents and Methods Using 1,2-Cyclohexanediones | TNNI3, CHD1, TNNT2 | ALDH1A1 1150/4885CYP1A2 3064/4885TSHR 786/4885 |
| US-11639366-B2 | Conjugation reagents and methods using 1,2-cyclohexanediones | TNNI3, CHD1, TNNT2 | ALDH1A1 1150/4885CYP1A2 3064/4885TSHR 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.